



Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

October 2, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in the following October investor and industry conferences. Details are below:

Cell & Gene Meeting on the Mesa

Date: Monday, October 6

Time: 8:00 AM MT – 9:00 AM MT

Format: Panel Discussion

Title: Future Horizons: Emerging Trends and Opportunities in Cell and Gene Therapy Development

Date: Monday, October 6

Time: 12:00 PM MT – 12:15 PM MT

Format: Company Presentation

Chardan Annual Genetic Medicines Conference

Date: Tuesday, October 21

Time: 12:00 PM ET – 12:40 PM ET

Format: Panel Discussion

Title: In Vivo Gene Therapies for Genetic Cardiac Diseases

The live webcast of the In Vivo Gene Therapies for Genetic Cardiac Diseases Panel Discussion may be accessed from the Investors section of [Tenaya's website](#). An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya's pipeline includes clinical-stage candidates TN-201, a gene therapy for *MYBPC3*-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for *PKP2*-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.

Tenaya Contacts

Michelle Corral

VP, Corporate Communications and Investor Relations

IR@tenayathera.com

Investors

Anne-Marie Fields

Precision AQ

annemarie.fields@precisionaq.com